Literature DB >> 21460243

Twenty-five years of peripheral blood stem cell transplantation.

Martin Körbling1, Emil J Freireich.   

Abstract

Peripheral blood stem cell transplantation (PBSCT) is the most common transplantation procedure performed in medicine. Its clinical introduction in 1986 replaced BM as a stem-cell source to approximately 100% in the autologous and to approximately 75% in the allogeneic transplantation setting. This historical overview provides a brief insight into the discovery of circulating hematopoietic stem cells in the early 1960s, the development of apheresis technology, the discovery of hematopoietic growth factors and small molecule CXCR4 antagonist for stem- cell mobilization, and in vivo experimental transplantation studies that eventually led to clinical PBSCT. Also mentioned are the controversies surrounding the engraftment potential of circulating stem cells before acceptance as a clinical modality. Clinical trials comparing the outcome of PBSCT with BM transplantation, registry data analyses, and the role of the National Marrow Donor Program (NMDP) in promoting unrelated blood stem-cell donation are addressed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460243     DOI: 10.1182/blood-2010-12-322214

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Supportive care in patients with acute leukaemia: historical perspectives.

Authors:  Giovanna Cannas; Xavier Thomas
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

2.  Peripheral blood-derived mesenchymal stem cells: candidate cells responsible for healing critical-sized calvarial bone defects.

Authors:  Shaowei Li; Ke-Jung Huang; Jen-Chieh Wu; Michael S Hu; Mrinmoy Sanyal; Min Hu; Michael T Longaker; H Peter Lorenz
Journal:  Stem Cells Transl Med       Date:  2015-03-05       Impact factor: 6.940

3.  Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone.

Authors:  Maria Rosa Lidonnici; Annamaria Aprile; Marta Claudia Frittoli; Giacomo Mandelli; Ylenia Paleari; Antonello Spinelli; Bernhard Gentner; Matilde Zambelli; Cristina Parisi; Laura Bellio; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini; Fabio Ciceri; Sarah Marktel; Giuliana Ferrari
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

4.  Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

Authors:  Marcos de Lima; Ian McNiece; Simon N Robinson; Mark Munsell; Mary Eapen; Mary Horowitz; Amin Alousi; Rima Saliba; John D McMannis; Indreshpal Kaur; Partow Kebriaei; Simrit Parmar; Uday Popat; Chitra Hosing; Richard Champlin; Catherine Bollard; Jeffrey J Molldrem; Roy B Jones; Yago Nieto; Borje S Andersson; Nina Shah; Betul Oran; Laurence J N Cooper; Laura Worth; Muzaffar H Qazilbash; Martin Korbling; Gabriela Rondon; Stefan Ciurea; Doyle Bosque; Ila Maewal; Paul J Simmons; Elizabeth J Shpall
Journal:  N Engl J Med       Date:  2012-12-13       Impact factor: 91.245

5.  High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Authors:  M Hengeveld; S Suciu; Y Chelgoum; J-P Marie; P Muus; F Lefrère; F Mandelli; F Pane; S Amadori; G Fioritoni; B Labar; F Baron; J Cermak; J-H Bourhis; G Storti; P Fazi; A Hagemeijer; M Vignetti; R Willemze; T de Witte
Journal:  Bone Marrow Transplant       Date:  2014-11-17       Impact factor: 5.483

Review 6.  Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2013-12-24

7.  High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation in children with advanced malignant solid tumors: A retrospective analysis of 38 cases.

Authors:  Wei-Ling Zhang; Y I Zhang; Tian Zhi; Dong-Sheng Huang; Yi-Zhuo Wang; Liang Hong; Xia Zhu; Ai-Ping Liu; Hui-Min Hu
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

8.  Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.

Authors:  Laura F Newell; Kelsea M Shoop; Rebekah J Knight; Sara N Murray; Rogelyn P Kwock; Carol E Jacoby; Susan Slater; Bryon E Allen; Casondra Ottowa; Brad Cota; Peggy L Appel; Rachel J Cook; Richard T Maziarz; Gabrielle Meyers
Journal:  Cytotherapy       Date:  2019-05-10       Impact factor: 5.414

9.  (89)Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies.

Authors:  Noriko Sato; Haitao Wu; Kingsley O Asiedu; Lawrence P Szajek; Gary L Griffiths; Peter L Choyke
Journal:  Radiology       Date:  2015-02-20       Impact factor: 11.105

Review 10.  The role of complement in the trafficking of hematopoietic stem/progenitor cells.

Authors:  Anna Janowska-Wieczorek; Leah A Marquez-Curtis; Neeta Shirvaikar; Mariusz Z Ratajczak
Journal:  Transfusion       Date:  2012-04-09       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.